Heartflow CMO Campbell Rogers sells $1.32 million in stock

Heartflow, Inc. (NASDAQ:HTFL) Chief Medical Officer Campbell Rogers sold 23,933 shares of common stock for a total value of $1,316,554 on October 22, 2026. The shares were sold at a price of $55.01 each. The timing of the sale comes as the stock has surged 95% year-to-date and currently trades at $57.01, near its 52-week high of $57.74. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, placing it among companies on the Most Overvalued list.

The transaction included the sale of 6,503 shares of common stock already held by Mr. Rogers, alongside 17,430 shares acquired through the exercise of stock options. These option exercises, totaling $114,024, involved 12,329 shares acquired at $8.33 per share and 5,101 shares acquired at $2.22 per share, representing prices ranging from $2.22 to $8.33. All these sales and option exercises were conducted under a Rule 10b5-1 trading plan adopted by Mr. Rogers on June 16, 2026.

One set of the exercised stock options was fully exercisable, while another portion vests in monthly installments until July 1, 2027, subject to continued service.

Following these transactions, Mr. Rogers directly holds 73,453 shares of Heartflow common stock. Additionally, he indirectly holds shares through various trusts, including 22,615 shares via the Campbell Rogers 2019 Irrevocable Trust, 46,159 shares via the CR Asset Protection Trust of 2023, 26,012 shares via a Spouse’s Trust, and 50,754 shares via The Campbell Rogers Revocable Trust. For deeper insights into HTFL’s valuation and 11 additional InvestingPro Tips, investors can access comprehensive analysis on the platform.

In other recent news, HeartFlow reported a narrower-than-expected loss for the second quarter of 2026, with adjusted earnings at negative $0.07 per share, surpassing Wall Street’s estimate of a negative $0.19. The company’s revenue increased by 48% year-over-year to $64.1 million, driven by strong demand for its coronary artery disease diagnostics. Stifel highlighted this revenue performance by raising its price target for HeartFlow to $45, noting the company’s outperformance in both its plaque and FFRct businesses. Meanwhile, Piper Sandler increased its price target to $64, emphasizing HeartFlow’s strong competitive position in the FFRct and plaque analysis market, supported by robust clinical data. Canaccord also raised its price target to $56, based on insights from an expanded survey of physicians using plaque analysis. These developments reflect HeartFlow’s strengthening position in the market and the positive sentiment from analysts.